• Publications
  • Influence
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.
Among children and adolescents aged 8 to 18, atomoxetine was superior to placebo in reducing ADHD symptoms and in improving social and family functioning symptoms.
Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study
OBJECTIVE: The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). METHOD: In a
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Atomoxetine appears to be an efficacious treatment for adult ADHD, and its lack of abuse potential may be an advantage for many patients.
Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia.
The view that HPA axis function is perturbed in patients with FM is supported, with a significant decrease in net integrated cortisol response to oCRH in FM patients, indicating adrenal hyporesponsiveness.
Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
One-third of patients who received methylphenidate followed by atomoxetine responded better to one or the other, suggesting that there may be preferential responders.
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial
The findings show that suvorexant was generally safe and well tolerated over 1 year of nightly treatment in patients with insomnia, with efficacy noted for subjective measures of sleep onset and maintenance.
Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults
While atomxetine has noradrenergic activity, increases in pulse and blood pressure were small and of little, if any, clinical significance, and atomoxetine was well tolerated in short- and long-term studies.
Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Youths with ADHD and comorbid ODD showed statistically significant improvement in ADHD, ODD, and quality-of-life measures, although the COMorbid group may require higher doses of atomoxetine.
ADHD rating scale IV: psychometric properties from a multinational study as clinician‐administered instrument
The psychometric properties of the ADHD Rating Scale IV (ADHD RS), clinician administered and scored, has been validated as a useful instrument to assess ADHD symptoms among American children and adolescents in a recent clinical trial conducted mainly in Europe.
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.
In patients who responded favorably to 12 weeks of initial treatment, atomoxetine was superior to placebo in maintaining response for the ensuing 9 months, and this result supports the value of maintenance treatment with atomxetine in patients with ADHD who respond to initial treatment.